Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 6Advanced Solid Tumor 4Solid Tumor, Adult 2Advanced Solid Tumors 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumor 1Patients With Advanced or Metastatic Solid Tumors 1Neoplasms 1Metastatic Solid Tumors 1Mesothelioma, Malignant 1Malignant Solid Tumour 1Locally Advanced or Metastatic Solid Tumors 1KRAS Mutant Solid Tumors 1

Interventions

Vorinostat 2pembrolizumab 1nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1DOXO-EMCH 1Cetuximab 1Bevacizumab 1BN 80927 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumour × Cetuximab × Other solid neoplasm × Clear all
NCT00388427 2015-05-28

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

University of Pittsburgh

Phase 1 Completed
31 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡